AstraZeneca is projected to report Q1 2026 revenue of $14.98 billion and core EPS of $2.57, with its current stock price of $189.71 trading below the average analyst price target of $222.94. The primary focus for investors remains the performance of the company's oncology segment, which continues to serve as the chief engine for top-line growth.
Supporting this momentum, the company recently progressed its oral obesity drug, elecoglipron, into Phase 3 trials as part of a strategic push to challenge industry leaders in the metabolic health market. Furthermore, recent regulatory wins, such as the FDA approval of the Saphnelo autoinjector, are expected to help offset headwinds from generic competition for the diabetes treatment Farxiga.